Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-09-16

FDA Approved: ONDANSETRON — Supplemental Application (Qilu Pharmaceutical Co., Ltd.)

View source ↗

Summary

FDA approved a supplemental application for ondansetron from Qilu Pharmaceutical Co., Ltd. under ANDA203711.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ondansetron (ondansetron)

Snippet

SUPPL AP for ONDANSETRON (ONDANSETRON)